BioAge Labs Inc., an American clinical-stage biotechnology company that develops therapies for obesity and metabolic diseases, raised approximately $200 million through its initial public offering (IPO) held last week on the US market, fiercebiotech.com reports.
Informatie preluata din publicatia "Bursa" - citeste integral articolul - click aici
Web Design by Dow Media | Gazduire Web by SpeedHost.ro